Categories Earnings, Health Care

Earnings Summary: Organon reports financial results for Q1 2024

Pharmaceutical company Organon & Co. (NYSE: OGN) has reported higher revenues and adjusted earnings for the first quarter of 2024.

  • First-quarter revenue was $1.62 billion, which is up 5% on a reported basis and 7% at constant currency
  • Women’s Health revenue increased by 11% and Biosimilars revenue climbed by 46%
  • Meanwhile, Established Brands revenue was flat on an as-reported basis during the quarter
  • Reported earnings per share and adjusted earnings per share were $0.78 and $1.22, respectively, during the three months
  • Net income came in at $201 million in the March quarter and adjusted EBITDA was $538 million
  • Gross margin was 59.0% on a reported basis and 62.1% on an adjusted basis in the first quarter
  • Adjusted EBITDA margin dropped to 33.2% in the first quarter from 33.7% last year

Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.

Most Popular

MU Earnings Preview: Strong Q2 results in cards amid growing AI demand

Micron Technology, Inc. (NASDAQ: MU) is uniquely positioned to capitalize on the AI wave sweeping the tech industry, leveraging its high-bandwidth-memory products designed for massive data processing tasks. The company

What to look for when FedEx (FDX) reports Q3 2025 earnings results

Shares of FedEx Corp. (NYSE: FDX) stayed green on Friday. The stock has dropped 14% over the past three months. The package delivery company is scheduled to report its third

Docusign (DOCU) Earnings: 4Q25 Key Numbers

Docusign, Inc. (NASDAQ: DOCU) reported total revenue of $776.3 million for the fourth quarter of 2025, up 9% year-over-year. Net income was $83.5 million, or $0.39 per share, compared to

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close